IW Capital leads £11m investment into Omni Pet to transform pet health
This week, we’re delighted to announce IW Capital’s investment in Omni Pet as part of the company’s £11 million Series A funding round – news you may already have seen featured in The Sunday Times.
Founded by veterinarian Dr Guy Sandelowsky and entrepreneur Shiv Sivakumar, Omni is tackling one of the fastest-growing challenges in pet health. As rates of obesity, allergies and digestive issues continue to rise among dogs, many owners remain unaware that some of the most common ingredients found in traditional pet food – including beef, chicken and dairy – are also among the leading causes of food allergies.
Omni is taking a different approach. Combining veterinary expertise with rigorous scientific research, the company has developed a range of nutrition products designed to improve long-term pet health while avoiding many of the common allergens associated with conventional pet food. The result is a rapidly growing brand that is helping thousands of pet owners make better-informed choices about their dogs’ wellbeing.
That approach is clearly resonating with consumers. Over the past 12 months, Omni has grown revenue by more than 10x, welcomed over 100,000 new customers since its appearance on Dragons’ Den and helped more than 300,000 dogs through its range of science-backed foods and supplements. The business is also consistently one of Amazon’s top-selling pet wellness brands.
Omni’s progress has attracted the backing of some of the UK’s most recognisable investors. Having first invested through Dragons’ Den, Deborah Meaden has chosen to increase her investment as part of this latest funding round.
As Deborah explains: “Pet health is becoming an increasingly important issue, with more dogs struggling with obesity, allergies and other chronic health conditions. What impressed me about Omni from the beginning was its commitment to combining science and innovation without compromising on sustainability or ethics to tackle these problems properly. The team have continued to execute exceptionally well, building a fast-growing brand with real purpose behind it. That progress is exactly why I chose to double down and reinvest.”
The new investment will support Omni’s next phase of growth including expanding its retail presence, accelerating customer acquisition and launching innovative new products. Among these is a natural, drug-free weight management supplement designed to help address rising levels of canine obesity.
At IW Capital, we back ambitious founders solving meaningful problems in large and growing markets. Omni combines clinical credibility with outstanding execution and a clear understanding of changing consumer demand, making it one of the most exciting businesses in the rapidly evolving pet health sector.
We’re proud to support the team as they continue their mission to help pets live healthier, happier lives.
